IDH1 and central nervous system cancer: Molecular features such as mutations in IDH1, ATRX, and P53 and codeletion of chromosome arms 1p and 19q have been widely recognized as clinically relevant markers of glioma [16], and patients bearing IDH1 mutation are expected to have a better prognosis [17].